Open Orphan #ORPH – AIM Schedule 1 update by Poolbeg Pharma plc

Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , notes the AIM Schedule One released in relation to Poolbeg Pharma plc (“Poolbeg”) this morning, 14 July 2021 at 8.00 a.m. updating on Poolbeg’s admission to AIM […]

The Times – Our flu drug is not to be sniffed at, says Poolbeg Pharma chief Jeremy Skillington

The course of Jeremy Skillington’s year took a fateful turn in March when he took a call from Cathal Friel, chairman of Open Orphan, a clinical trials company listed on the Alternative Investment Market (AIM). At the time Skillington was tidying up the loose ends of the landmark €380 million sale of Irish biotech company […]